Limited evidence for paracetamol and/or NSAIDs in acute otitis media

Limited evidence for paracetamol and/or NSAIDs in acute otitis media

PEARLS No.
731
Clinical question

How effective is paracetamol or NSAIDs, alone or combined, compared with placebo or no treatment, in relieving ear pain in children with acute otitis media (AOM)?

Bottom line

Paracetamol and ibuprofen as monotherapies may be more effective than placebo in relieving pain at 48 hours. For paracetamol versus placebo, the proportion of children with pain was 10% versus 25% (relative risk 0.38; 95% confidence interval 0.17–0.85; number needed to treat to benefit 7; low-certainty evidence). For ibuprofen versus placebo, the proportion of children with pain was 7% versus 25% (RR 0.28; 95% CI 0.11–0.70; NNTB 6; low-certainty evidence).

The evidence is very uncertain for the effectiveness of ibuprofen versus paracetamol in relieving pain in children with AOM, as well as for ibuprofen plus paracetamol versus paracetamol alone, thereby preventing any firm conclusions.

Adverse events occurred infrequently, and limited data were available for analysis. The evidence for the effects of paracetamol and ibuprofen, alone or combined, on adverse events is very uncertain.

Caveat

In some of the trials, AOM was diagnosed either by the GP or research nurse without further specification of diagnostic criteria applied. Due to such issues as study limitations and questions about the applicability of the evidence, confidence in the evidence is low for all comparisons.

Context

AOM is one of the most common childhood infectious diseases. Pain is the key symptom of AOM and central to children’s and parents’ experience of the illness. Because antibiotics provide only marginal benefits, analgesic treatment including paracetamol and NSAIDs is regarded as the cornerstone of AOM management.

Cochrane Systematic Review

de Sévaux JLH et al. Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. Cochrane Database Syst Rev 2023;8:CD011534. This review contains 4 trials with a total of 411 participants.